Oculis Holding AG Pioneers Genotype-Based Precision Approach to Dry Eye Disease Treatment
Source: Streetwise Reports  (6/13/26)
Oculis Holding AG launches the PREDICT-1 trial for licaminlimab, targeting patients with a specific TNFR1 genotype to address unmet needs in the large dry eye disease market. More >

MindBio Therapeutics Positions Voice AI Technology for Growth in Safety-Critical Sectors
Source: Streetwise Reports  (6/12/26)
Explore how MindBio Therapeutics is advancing voice-based AI detection for intoxication across mining, aviation, and other industries, backed by strong market trends and analyst targets. More >

Biopharma Co. Trials Precision Medicine Breakthrough for Dry Eye Disease. Gets Positive Results
Source: Streetwise Reports  (6/12/26)
Oculis Holding AG (OCS:NASDAQ; OCS:XICE) launches PREDICT-1, a genotype-based trial for licaminlimab, targeting 10M moderate-to-severe dry eye patients. More >

Biotech Firm Deploys Revolutionary Intox AI, Unlocking Billion-Dollar Industrial Safety Opportunity
Source: Streetwise Reports  (6/10/26)
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) launches Intox AI, detecting intoxication via voice, targeting mining and aviation in a US$2.06B market. More >

ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market
Source: Streetwise Reports  (6/10/26)
Explore how ORIC Pharmaceuticals is advancing its oncology pipeline with key catalysts ahead, amid rising global demand for innovative cancer treatments and strong analyst support. More >

Clinical-Stage Biopharma Co. Issues New Inducement Stock Options for Growth
Source: Streetwise Reports  (6/8/26)
ORIC Pharmaceuticals Inc. (ORIC:NASDAQ) granted 34,800 stock options and 5,900 restricted stock units to new employees as analysts issue "Buy" ratings for the year ahead. More >

Cancer Drug Developer Shifts 70% of Spending to Research as AI Pipeline Progresses
Source: Streetwise Reports  (6/5/26)
Rakovina Therapeutics (TSX.V: RKV) reported lower net losses, reduced administrative spending, debt restructuring, financing activity, and progress across its AI-driven oncology pipeline in Q1 2026. More >

California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60%
Source: Streetwise Reports  (6/4/26)
Revolution Medicines Inc.'s (RVMD:NASDAQ) daraxonrasib treats pancreatic cancer patients, doubling median survival. Analysts rate it a "Buy" with targets up to US$263. More >

US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug
Source: Streetwise Reports  (6/1/26)
Capricor Therapeutics Inc.'s (CAPR:NASDAQ) Deramiocel targets FDA approval by August 2026, with analysts issuing Buy ratings and price targets as high as US$60. More >

Biopharma Company Reveals High-Impact SCI Recovery Gains
Source: Streetwise Reports  (5/28/26)
NervGen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) reports 100% responder rates for NVG-291 in spinal cord injury trials, strengthening hopes for major recovery breakthroughs. More >

Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles
Source: Dr. Yun Zhong  (5/20/26)
Keros Therapeutics (KROS:NASDAQ) disclosed that initiation of its Phase 2 rinvatercept study in Duchenne muscular dystrophy will slip from 2Q26 to 3Q26 due to procedural regulatory delays, according to a Wedbush research note. More >

Lexington, MA Biopharma Co. Reports Q1 2026 Financials, Makes R&D Plans
Source: Streetwise Reports  (5/20/26)
Keros Therapeutics Inc. (KROS:NASDAQ) lowered research spending & reported funding through 2028 as analysts monitor upcoming trial catalysts for ALS & Muscular Dystrophy drugs. More >

FDA Fast Track Designation Boosts ALS Treatment Outlook; Analyst Sees More Than 250% Upside Potential
Source: Jason Kolbert  (5/12/26)
D. Boral Capital analyst Jason Kolbert reiterated his rating and price target on Coya Therapeutics Inc. (COYA:NASDAQ) following the company's receipt of FDA Fast Track Designation for COYA 302 in ALS. More >

California Biotech Co. Discovers VOXZOGO Breakthrough, Reports Strong Q1
Source: Streetwise Reports  (5/11/26)
BioMarin Pharmaceuticals Inc. (BMRN:NASDAQ) delivered positive long-term achondroplasia data alongside rising revenues, accelerating rare disease portfolio growth. More >

FDA Rejects Melanoma Drug Again as Analysts Slash Targets and Approval Path Comes Under Fire
Source: Streetwise Reports  (5/8/26)
Replimune Group Inc. (REPL:NASDAQ) received a second FDA rejection for RP1 in advanced melanoma, prompting analyst downgrades, price target cuts, and renewed debate over approval standards for cancer therapies. More >

Biotech Innovator Niagen Uncovers Breakthrough NAD+ Booster, Reports Strong Q1 Results
Source: Streetwise Reports  (5/8/26)
Niagen Bioscience Inc. (NAGE:NASDAQ) reports a 3% increase in total net sales to US$31.5 million for the first quarter. Read why analysts recommend this stock in a rapidly expanding market. More >

Sublingual Drug Reformulator Expands into Caffeine Market and Gets Capital Injection
Source: Stewart Thomson  (5/8/26)
Technical Analyst Stewart Thomson reviews Aspire Biopharma Holdings, Inc. (ASBP:NASDAQ) in light of its recent news. More >

Oncology Company Given Neutral Rating as Q1/26 Beat Sets Up Catalyst
Source: Dr. David Nierengarten  (5/7/26)
Wedbush Securities reiterated a Neutral rating on Novocure Ltd. (NVCR:NASDAQ) after the company posted a Q1/26 revenue beat of US$174.1 million, raised FY26 guidance to US$690710 million, and reported encouraging early Optune Pax launch metrics. More >

Three AI-Driven Cancer Programs Advance Toward Key 2026 Milestones
Source: Streetwise Reports  (5/6/26)
Rakovina Therapeutics Inc. (RKV:TSX.V) reported 2025 financial results and outlined progress across its kt-5000, kt-3283, and kt-2000 programs, alongside financing, leadership updates, and ongoing AI partnerships. More >

MA Biotech Downgraded to Neutral After Second FDA CRL for RP1 Melanoma BLA
Source: Dr. Robert Driscoll  (5/6/26)
Wedbush Securities downgraded Replimune Group Inc. (NASDAQ:REPL) to NEUTRAL after the FDA issued a second complete response letter for RP1 in PD-1 refractory melanoma. More >

Oncology Co. Tests Advanced Cancer Treatments, Reports Q1 2026 Financial Results
Source: Streetwise Reports  (5/6/26)
Novocure Ltd. (NVCR:NASDAQ) posted 12% revenue growth, strong international patient gains, FDA momentum, and promising pancreatic cancer trial results in 2026.

More >

Biotech Downgraded to Neutral After Second FDA CRL for Reproxalap in Dry Eye Disease
Source: Matthew Caufield  (5/5/26)
H.C. Wainwright & Co. downgraded Aldeyra Therapeutics Inc. (ALDX:NASDAQ) to Neutral and slashed its price target after the company received a second FDA Complete Response Letter for its Reproxalap NDA in dry eye disease. More >

Biotech Co. Faces Mounting ELEVIDYS Efficacy Risk as Roche Phase 3 Study Threatens US Franchise
Source: Mitchell Kapoor  (5/4/26)
H.C. Wainwright analysts argue that Roche's new placebo-controlled Phase 3 study of ELEVIDYS, while aimed at reopening the European market, creates significant downside risk for Sarepta Therapeutics Inc.'s (SRPT:NASDAQ) core U.S. ambulatory business by potentially generating another failed NSAA readout. More >

Wedbush Sees Denifanstat as Front-Line Acne Therapy with 249% Upside Potential
Source: Dr. Yun Zhong  (5/1/26)
Wedbush Securities analyst Dr. Yun Zhong reiterated a price target on Sagimet Biosciences (SGMT:NASDAQ), implying roughly 249% upside. More >

California Biopharma Co. Uncovers Massive Oncology Breakthrough
Source: Streetwise Reports  (4/28/26)
Nurix Therapeutics Inc. (NRIX:NASDAQ) new cancer pipeline data highlights powerful targeted protein degradation advances, with analysts projecting 92% upside potential. More >